Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
Bill Alpert
·3 min read
Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead
Crispr Therapeutics Chief Executive Sam Kulkarni says the next two years of clinical trials and data readouts will give investors, and patients, plenty to cheer about.